FDA accepts Ascendis Pharma’s TransCon hGH BLA for pediatric GHD
Ascendis Pharma, a Danish biopharma company, said that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for TransCon hGH (lonapegsomatropin) for the treatment for pediatric growth hormone deficiency (GHD). TransCon hGH is an investigational long-acting prodrug of somatropin (human growth hormone or hGH). The FDA has set a Prescription […]